Baseline Laboratory Tests and Preparations Before Amphotericin B Lipid Formulation
Before administering amphotericin B lipid formulation, obtain baseline renal function (serum creatinine and BUN), complete blood count, liver function tests, and serum electrolytes (particularly potassium and magnesium), and ensure adequate hydration with saline loading. 1, 2
Essential Baseline Laboratory Tests
The FDA label and multiple IDSA guidelines consistently emphasize specific baseline monitoring requirements 2:
Required Baseline Labs:
- Renal function: Serum creatinine and blood urea nitrogen (BUN)
- Complete blood count (CBC): To assess for baseline anemia and cytopenias
- Liver function tests: Aminotransferases (AST/ALT), bilirubin
- Serum electrolytes:
- Potassium (critical - amphotericin B causes hypokalemia)
- Magnesium (commonly depleted)
- Sodium, chloride, bicarbonate
- Hemoglobin concentration: Baseline anemia assessment
Additional Baseline Assessments:
- ECG: Particularly important given the risk of QTc prolongation from hypokalemia and arrhythmias 1, 2
- Urinalysis: May be prudent in some patients 1
Pre-Administration Preparations
Hydration and Electrolyte Management:
Saline loading prior to amphotericin B administration reduces nephrotoxicity risk 2. The FDA label specifically states: "In some patients hydration and sodium repletion prior to amphotericin B administration may reduce the risk of developing nephrotoxicity."
- Administer intravenous saline before infusion
- Ensure adequate sodium repletion
- Consider supplemental alkali medication to decrease renal tubular acidosis complications 2
Premedication Strategy:
Premedicate with diphenhydramine to reduce infusion-related reactions, particularly for lipid formulations where acute reactions occur in approximately 20% of patients 3, 4. Common infusion reactions include:
- Fever and rigors
- Hypotension
- Nausea/vomiting
- Headache
- Tachypnea
These reactions typically occur 1-3 hours after starting infusion and are more severe with initial doses 2.
Test Dose Consideration:
The manufacturer recommends a 1 mg test dose for conventional amphotericin B deoxycholate 2. However, for lipid formulations in severe infections, delaying therapeutic dosing with incremental increases may be detrimental 5. The decision should balance infection severity against reaction risk.
Ongoing Monitoring Schedule
Once therapy begins, monitor renal function frequently (at least once or twice weekly) along with:
- Serum chemistry values (electrolytes, liver function)
- CBC
- Hemoglobin concentrations 2
More frequent monitoring is indicated for:
- Patients with pre-existing renal impairment
- Concurrent nephrotoxic medications (aminoglycosides, cyclosporine, pentamidine)
- Clinical deterioration
- Electrolyte abnormalities requiring correction 2
Critical Drug Interactions to Screen
Before administration, review medications for:
- Other nephrotoxic agents: Aminoglycosides, cyclosporine, pentamidine - require intensive renal monitoring 2
- Digitalis glycosides: Amphotericin-induced hypokalemia potentiates digitalis toxicity 2
- Corticosteroids/ACTH: Potentiate hypokalemia and cardiac dysfunction risk 2
- Skeletal muscle relaxants: Enhanced curariform effects from hypokalemia 2
Special Populations
Avoid leukocyte transfusions during or shortly after amphotericin B infusion due to acute pulmonary toxicity risk; separate these infusions as far as possible temporally 2.
For patients with reduced renal function at baseline (creatinine ≥2.5 mg/dL), lipid formulations are preferred over conventional amphotericin B deoxycholate, but still require careful monitoring 3, 6.